Table 2.
Disease characteristics of patients with RA by therapy history at time of enrollment into Corrona
| Characteristic | No identified RA-directed therapy N = 750 n (%) |
Prior RA-directed therapy N = 34,735 n (%) |
P valuea |
|---|---|---|---|
| Duration of RA (years) | |||
| Mean ± SD | 5.5 ± 9.0 | 9.0 ± 9.7 | <0.0001 |
| Median | 1 | 6 | |
| % ≤1 year | 380 (50.7) | 7971 (22.9%) | |
| Age at RA onset (years), mean ± SD | 52.3 ± 15.4 | 49.2 ± 14.8 | <0.0001 |
| Rheumatoid Factor (RF) positivity | 290 (69.4%) | 13,090 (69.7%) | 0.8850 |
| CCP positivity | 154 (60.6%) | 7362 (63.4%) | 0.3620 |
| CDAI, mean ± SD | 18.3 ± 15.0 | 14.3 ± 13.1 | <0.0001 |
| Disease activity | |||
| Low | 256 (38.4%) | 16,233 (48.7%) | <0.0001 |
| Moderate | 184 (27.6%) | 9559 (28.7%) | |
| High | 227 (34.0%) | 7527 (22.6%) | |
| mHAQ, mean ± SD | 0.41 ± 0.48 | 0.37 ± 0.46 | 0.0559 |
| Patient global assessment, mean ± SD | 36.3 ± 28.2 | 31.7 ± 26.7 | <0.0001 |
| Physician global assessment, mean ± SD | 30.8 ± 23.1 | 24.8 ± 21.8 | <0.0001 |
| Patient reported pain, mean ± SD | 41.8 ± 28.7 | 34.3 ± 27.8 | <0.0001 |
| Patient reported fatigue, mean ± SD | 35.6 ± 31.4 | 38.3 ± 30.4 | 0.2509 |
| Reported morning stiffness | 581 (82.5%) | 24,541 (73.5%) | <0.0001 |
| % Duration ≥1 h | 349 (49.6%) | 13,762 (41.2%) | <0.0001 |
| NSAID use | 404 (87.1%) | 18,490 (84.3%) | 0.0980 |
| Analgesics use | 375 (50.1%) | 19,381 (55.9%) | 0.0010 |
RA rheumatoid arthritis, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, mHAQ Modified health assessment questionnaire, SD standard deviation
a P value from Student’s two-sample two-sided t test (continuous variables) and Chi-squared test (categorical variables) comparing patients having no identified RA-directed therapy at time of enrollment to those with RA-directed therapies